Showing results (151-160 of 437) with videos related to

Sort By:
Pageof 44
Blood Cancer Journal|December 18, 2023
Addressing the disparities: the approach to the African American patient with multiple myelomaManisha Bhutani, Brandon J Blue, Craig Cole, et al.
British Journal of Haematology|May 19, 2018
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trialPaul G Richardson, Robert L Schlossman, Anuja N Roy, et al.
The American Journal of Gastroenterology|February 28, 2007
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control studyYasser H Shaib, Hashem B El-Serag, Ajay K Nooka, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
Expert Review of Clinical Pharmacology|October 28, 2015
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomesPaul G Richardson, R Donald Harvey, Jacob P Laubach, et al.
JAMA Oncology|August 22, 2018
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical TrialAjay K Nooka, Michael Luhua Wang, Andrew J Yee, et al.
British Journal of Haematology|January 12, 2011
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancersPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Cancer Letters|July 31, 2018
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacyGuoqing Qian, Weilong Yao, Shuo Zhang, et al.
The Journal of Biological Chemistry|December 25, 2007
Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529Sumin Kang, Shaozhong Dong, Ailan Guo, et al.
Expert Review of Hematology|September 29, 2025
Current experiences with teclistamab in patients with multiple myeloma and renal impairmentMeletios A Dimopoulos, Yael C Cohen, Aurore Perrot, et al.
Pageof 44